MedTrace Logo

Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography

NCT07409753 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-13

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if oxytocin reduces pain in a small area of skin after pulses of non-burning heat by changing how nerves in the heated area react to pressing a thin, bendable plastic bristle and a thick, non-bending plastic bristle in adult, healthy participants. The man questions it aims to answer are:

Does oxytocin increase the number of times a fiber which normally responds only to the thin bristle fires (sends a signal) after the heat pulses.

Does oxytocin raise the number of times a fiber which normally responds only to the thick bristle fires (sends a signal) after the heat pulses.

Researchers will compare oxytocin to a placebo (a look-alike substance that contains no drug) to see if oxytocin ABC works to change how nerves react to light touch and painful pressing in an area of sensitized skin.

Participants will:

Receive an intravenous injection of oxytocin or placebo on one occasion On the same day, a needle will be put near nerve fibers to record their firing before and after a few cycles of short heating of the skin.

Conditions

  • Acute Pain

Interventions

DRUG

Intravenous Oxytocin

Intravenous oxytocin, 20 IU will be administered via two 30-minute infusions separated by 30 minutes

DRUG

Intravenous Placebo

Intravenous placebo will be infused in the same volume and timing as the intravenous oxytocin intervention

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Linkoeping University

    collaborator OTHER_GOV

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • James Eisenach, MD · Atrium Health Wake Forest University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-22
Primary Completion
2027-06-01
Completion
2027-06-08

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07409753 on ClinicalTrials.gov